Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences develops investigational cancer medicines for patients and the doctors who treat them. It last closed at $16.40 on Nov 17, down 2.84% on the day. The average 12-month price target from 4 analysts is $44.25 (+169.8% from the last close), with a high of $50.00 and a low of $41.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints totaling $3.4M, the largest $2.0M.
Key Stats
Last 12 monthsNot reported for this period.
From RCUS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on RCUS in the past 90 days. The average target is $44.25, with a high of $50.00 and a low of $41.00, compared with the last close of $16.40.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | Wedbush | Target lowered | Buy | $49 → $45 |
| Oct 21 | Citigroup | Maintained | Buy | $50 |
| Oct 21 | Truist Securities | Target raised | Buy | $40 → $41 |
| Oct 21 | Wedbush | Target raised | Buy | $43 → $49 |
| Oct 14 | JP Morgan | Initiated | Buy | $41 |
Technical Analysis
The stock is 11% below its 20 day and 35% below its 50 day average. It is 49% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the 52 week low at $16.33, and the nearest resistance the Pivot at $16.60.
| RSI (14) | 31.23 | Weak, oversold below 30 | Neutral |
| MACD | -1.45 | Above its signal line | Bullish |
| Stochastic | 7.1 | Near the bottom of its range | Oversold |
| ADX (14) | 31.1 | Trending down | |
| Williams %R | -97.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -200.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −13.4% | Change over 10 sessions | Bearish |
| ATR (14) | $1.14 | Typical daily range, 7.0% of price |
| RSI (14) | 28.66 | Oversold below 30 | Oversold |
| MACD | -1.92 | Below its signal line | Bearish |
| Stochastic | 3.0 | Near the bottom of its range | Oversold |
| ADX (14) | 26.4 | Trending down | |
| Williams %R | -99.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -147.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −33.3% | Change over 10 sessions | Bearish |
| ATR (14) | $2.90 | Typical daily range, 17.7% of price |
What happened before
See how RCUS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RCUS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in RCUS in the last 90 days.
Dark Pool
30DRCUS Institutional Ownership
Full report →- ▲132 buying vs 102 selling
- ▲Held by funds +1.6 pts
- ▲Funds holding +14
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 244 | 230 | +6.1% |
| In funds' top 10 | 5 | 6 | −16.7% |
| Held by funds | 86.8% | 85.2% | +1.6 pts |
| New / increased | 47 / 85 | 43 / 87 | +1.5% |
| Reduced / sold out | 72 / 30 | 63 / 24 | +17.2% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCUS is in one of them and how their past RCUS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RCUS in an article yet. Here's the latest on the wider market.
RCUS Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $1K – $15K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Donald J TrumpExecutive branch | Sell | $15K – $50K | May 15, 2026 | Jul 1, 2026 | 47 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Arcus Biosciences
Arcus Biosciences is a biopharmaceutical company based in Hayward, California. It develops investigational medicines, mainly for cancer, and tests them in clinical trials carried out with contract research organizations and trial sites. Its products are still investigational, and it works with partners such as AstraZeneca, Gilead and Taiho on some of its programs. Its intended users are cancer patients and the doctors who treat them.
- Headquarters
- Hayward, CA
- Founded
- 2015
- Website
- arcusbio.com ↗




